Keck School of Medicine of USC | Neurology Department
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
586 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Reference Study ID Number: BN42358 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal